Zanubrutinib for the treatment of lymphoid malignancies: Current status and future directions
Zanubrutinib (BGB-3111, Brukinsa®, BeiGene) is a next-generation irreversible inhibitor of Bruton’s tyrosine kinase (BTK), developed by BeiGene in 2012 for the treatment of B-cell malignancies. It was designed to minimize off-target inhibition of TEC- and EGFR-family kinases. Zanubrutinib is more se...
Guardado en:
| Autores principales: | , |
|---|---|
| Formato: | Artigo |
| Lenguaje: | Inglês |
| Publicado: |
Frontiers Media S.A.
2023-03-01
|
| Colección: | Frontiers in Oncology |
| Materias: | |
| Acceso en línea: | https://www.frontiersin.org/articles/10.3389/fonc.2023.1130595/full |
| Etiquetas: |
Sin Etiquetas, Sea el primero en etiquetar este registro!
|